For Patients

The goal of IMMUcan is to understand, how the immune system and tumours interact, and the impact of therapeutic interventions.

Patient information leaflet
Join us
IMMUcan Patient Corner - Illustration
IMMUcan Patient Corner - Illustration

What is IMMUcan?

IMMUcan is a group of university and industry partners that collects tumour material and clinical data from several thousand cancer patients. The group generates biological data for research that is being made available for the scientific community.

Many opportunities for collaboration
What are the benefits for patients?

01.

Receive additional information
on your tumour.

However, we cannot guarantee that this will have a direct benefit for you.

02.

Contribute to improving our understanding of cancer.

03.

Have a major impact on current and future treatments.

“IMMUcan stands for “Integrated iMMUnoprofiling
of large adaptive CANcer patient cohorts

What is the aim of IMMUcan?

The tumour microenvironment consists of cancer cells, and other various non-tumour cells that are directly in or around the tumour, such as immune cells. The cancer research community believes that many factors within this environment influence how the tumour reacts to cancer treatments.

The hope is
  • to better understand why some patients respond to certain treatments and others not

  • find clues in the microenvironment for future treatment options.

IMMUcan Patient Corner - Illustration
IMMUcan Patient Corner - Illustration
IMMUcan Patient Corner - Illustration
IMMUcan Patient Corner - Illustration

What will IMMUcan deliver?

IMMUcan will deliver an understanding of the tumour microenvironment and how it evolves under the influence of cancer treatment, using tumour samples from some 3000 patients combined with clinical data.

Samples will include the tumour, stool, saliva or blood from patients diagnosed with colorectal, lung, head and neck, breast or renal cancers.

Timelines and funding

IMMUcan receives support from the European Union (grant 821558) within the Innovative Medicine Initiative 2 program and from the European Federation of Pharmaceutical Industries.

The project runs from March 2019, and will end in August 2024.

Who are we?

JOIN US!

We are looking for volunteers to be our
patient partners
and sample donors.

If you are a lung, head and neck, breast renal, or colorectal cancer patient,
ask your doctor how you could participate.
Patients are recruited via the EORTC SPECTA program.

Participate
IMMUcan Patient Corner - Illustration

Why be part of IMMUcan?

By taking part in this project your clinician will receive additional information on your tumour. However, we cannot guarantee that this will have an immediate benefit for you. BUT Your participation can help us better understand cancer and have a major impact on current and future treatments.